THERAPEUTIC CLASS

Novel therapies for diabetic kidney disease

---

Over the past 30 years there have been many complementary therapies developed to achieve glycemic control and have an impact on cardiovascular outcomes, as well as reduce the risk of microvascular disease. The 2 most notable new entries have been the sodium–glucose
cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide-1 (GLP-1) agonists. Both these classes of agents have demonstrated reductions in cardiovascular event rates as well as reductions in blood pressure and weight.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Endocrine & Metabolic system
Cardiovascular & Hematopoietic System

Specific Detail Info

Kidney International Supplements (2018) 8, 18–25;

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment